Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
July 20 2017 - 06:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain, and various types of cancer, today announced the appointment
of Andrew J. Cole, M.D., F.R.C.P.(C.) to its Scientific Advisory
Board.
Dr. Andrew J. Cole is Director of the MGH
Epilepsy Service, Chief of the Division of Clinical Neurophysiology
and Epilepsy and Professor of Neurology at Harvard Medical
School. He graduated from Dartmouth College Magna Cum Laude and
Dartmouth Medical School. He trained in Neurology and Clinical
Neurophysiology at the Montreal Neurological Institute, and then
moved to Johns Hopkins University School of Medicine where he was
Assistant Professor of Neurology. He came to Massachusetts General
Hospital in 1992 where he started and developed the MGH Epilepsy
Service and founded the MGH Pediatric Epilepsy Service. He has
published extensively in clinical neurology, epilepsy, clinical
neurophysiology and basic neuroscience. In addition to research and
clinical work, Dr. Cole lectures frequently throughout the United
States and internationally, and has been a visiting professor at
numerous institutions in the U.S.A. and abroad.
"I am impressed with Anavex and its potential
CNS platform drug, ANAVEX 2-73, which has shown encouraging
clinical safety data combined with promising preclinical
anti-seizure data," said Andrew J. Cole, M.D., F.R.C.P.(C.),
Director of the Massachusetts General Hospital Epilepsy Service and
Professor of Neurology at Harvard Medical School. “I look forward
to advising the company as it’s about to initiate three clinical
trials with significant unmet needs.”
“We are pleased to welcome Dr. Andrew Cole to
Anavex’s Scientific Advisory Board,” stated Christopher U.
Missling, PhD, President and Chief Executive Officer of Anavex.
“Dr. Cole brings extensive experience in neurological diseases to
Anavex. I am confident he will make important contributions to our
SAB and to the continued development of ANAVEX 2-73 for the
treatment of both neurodevelopmental and neurodegenerative
diseases, including Rett syndrome, Parkinson’s disease and
Alzheimer’s disease.”
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain, and various types of cancer. Anavex’s lead drug candidate,
ANAVEX 2-73, recently completed successfully a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. It has also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy and others. The Michael J. Fox Foundation for
Parkinson’s Research has awarded Anavex a research grant to develop
ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund
a preclinical study, which could justify moving ANAVEX 2-73 into a
Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting
sigma-1 and M1 muscarinic receptors, is a promising preclinical
drug candidate demonstrating disease modifications against the
major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available
at www.anavex.com. You can also connect with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com
Media:
Dennis Dobson, Jr.
Dobson Media Group
203-258-0159
dennisdobsonjr@dobsonmediagroup.com
Social Media:
Bill Douglass
Gotham Communications
646-504-0890
bill@gothamcomm.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2023 to Mar 2024